Technical Data
044723
DAPT (N-S-phenylglycine tert.butyl ester)
5mg
Biochemicals Storage: 4C/-20CShipping: Blue Ice
Cell permeable gamma-secretase inhibitor (IC50 = 115 nM for total beta-amyloid, IC50 = 200 nM for beta-amyloid 1-42). Reduces Abeta levels in vivo. Blocks the proteolytic processing of neurotrophin receptor alike death domain protein (NRADD). Does not inhibit persenilinase. Notch processing inhibitor. Enhances neuronal differentiation independent of sonic hedgehog (Shh) signaling. CDK5 activity inhibitor. Apoptosis enhancer.

Storage and Stability:
Short-term Storage: +4C
Long-term Storage: -20C
Stable for at least 2 years after receipt when stored at -20C.

CAS Number:
208255-80-5

Molecular Formula:
C23H26F2N2O4

Molecular Weight:
432.5
Purity: >98% (NMR)

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Product Reference:
Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain: H.F. Dovey, et al.; J. Neurochem. 76, 173 (2001)
The gamma-secretase inhibitor N--S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice: T.A. Lanz, et al.; J. Pharmacol. Exp. Ther. 305, 864 (2003)
Release of a membrane-bound death domain by gamma-secretase processing of the p75NTR homolog NRADD: K. Gowrishankar, et al.; J. Cell. Sci. 117, 4099 (2004)
Presenilin endoproteolysis mediated by an aspartyl protease activity pharmacologically distinct from gamma-secretase: W.A. Campbell, et al.; J. Neurochem. 85, 1563 (2003)
A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish: A. Geling, et al.; EMBO Rep. 3, 688 (2002)
The notch response inhibitor DAPT enhances neuronal differentiation in embryonic stem cell-derived embryoid bodies independently of sonic hedgehog signaling: T.Q. Crawford & H. Roelink; Dev. Dyn. 236, 886 (2007)
The Notch signaling inhibitor DAPT down-regulates cdk5 activity and modulates the distribution of neuronal cytoskeletal proteins: J. Kanungo, et al.; J. Neurochem. 106, 2236 (2008)
DAPT enhances the apoptosis of human tongue carcinoma cells: B.E. Grottklau, et al.; Int. J. Oral Sci. 1, 81 (2009)


Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.